FSADFemale Sexual Arousal Disorder
FSADFoundation Studies in Art and Design (University of Gloucestershire; Cheltenham, UK)
FSADFiber Science & Apparel Design (course of study; Cornell University; Ithaca, NY)
FSADField-Safe Application Debugger
FSADFull Scale Advanced Development
FSADForce Structuring Analysis Division
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
As discussed above, more than a decade later, the DSM-5 merged the prior distinct diagnoses of HSDD and FSAD from the DSM-IV-TR into the current FSI/AD.
He also interacted with FSAD students and faculty, gave guest lectures in classes, and provided advice and critiqued student work.
NuGyn markets Eros Therapy, a medical device that was cleared by the FDA, through a 510(k) process, to treat Female Sexual Arousal Disorder (FSAD) in April 2000.
"Now we are beginning to establish the pathways involved in sexual arousal scientists may be able to find ways of helping women who would like to overcome FSAD."
One exception was a placebo-controlled trial in which sildenafil was associated with significant benefits in postmenopausal women with FSAD who had normal (protocol-specified) levels of estradiol and free testosterone (or were receiving estrogen and/or androgen replacement therapy).
Recent studies have suggested that FSAD affects about 43% of women, and there are no Rx counterparts to Viagra to treat the problem.
Although some women who have FSAD do complain chiefly of genital impairment, other women report that although their bodies become aroused, they do not become aroused psychologically.
All of the participants responded to the erotic film with perceived autonomic arousal and perceived physical arousal, but the women with FSAD reported less arousal, the researchers said.
The "at-home" study was conducted at multiple research sites in the U.S to evaluate the efficacy and safety of Femprox(r) cream in 94 pre-menopausal women diagnosed with FSAD. The trial results demonstrated positive dose-related trends, and the side effects noted were mostly mild in nature and short in duration.
The grant was given to the Federation of Sports Associations for the Disabled (Wales) (FSAD) to mark the UK's participation in the European Year of Disabled People 2003.
The company presented data from a single dose in-clinic safety and efficacy trial with ALISTA, its topical alprostadil formulation to treat FSAD, at the 2002 AUA.
Female sexual arousal disorder (FSAD) is defined as a persistent and pervasive lack of lubrication and genital sensation, which causes the patient distress.